BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
Jul 07, 2003
 |  BioCentury  |  Finance

Have approvals, will travel

For the second quarter in a row, approvals out-numbered significant late-stage setbacks by nearly 2-1. But unlike the first quarter, in which good news didn't lure investors to the sector, the recent glut of good news drove buyers into biotech. In addition to the spate of product approvals, several clouds were lifted on key compounds as companies provided new, positive data for Erbitux cetuximab from ImClone Systems Inc. (IMCLE), Bristol-Myers Squibb Co. (BMY)...

Read the full 357 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >